Rapport Therapeutics, Inc. Stock 12‑Month Price Target Cut to $65.43, Implies 157% Upside

What happened

Rapport Therapeutics’ average 12-month stock price target, based on estimates from 14 analysts, fell from $68.29 to $65.43. The updated target implies about 157% upside from the Nov. 3 closing price. The consensus rating remained Buy among 16 analysts.

Confirmed

Global impact / market context

The lower target shows analysts have reduced their average expected value, which may temper investor expectations. Yet the stated upside and unanimous Buy ratings point in the opposite direction. Those views can influence demand for the shares, but targets are forecasts, not guaranteed outcomes.

Analyst inference

The figures describe analyst expectations rather than Rapport’s reported sales, costs, or cash available, so they do not establish a change in the company’s business performance. The target range of $50 to $89 also shows meaningful disagreement about its potential value.

Confirmed

What to watch

1. Track future target revisions and the reasons analysts give; further reductions could signal worsening expectations, while increases could indicate greater confidence in the company’s outlook. Analyst inference
2. Compare later analyst ratings with the current 16 Buys and no Holds or Sells to see whether the unanimous recommendation changes. Confirmed
3. Check the share price against the Nov. 3 closing-price reference used for the 157% upside calculation; a different price changes the implied upside. Analyst inference

Evidence

• Original source link unavailable